MAP3K7 and ovarian carcinoma: TAK1 has been confirmed to enhance the oncogenesis and aggressiveness of ovarian cancer cells, and analysis of TCGA and other databases revealed that TAK1 expression in tumors is negatively correlated with ovarian cancer patient survival.